Literature DB >> 3126239

Exposure of mice to live Pseudomonas aeruginosa generates protective cell-mediated immunity in the absence of an antibody response.

R B Markham1, W G Powderly.   

Abstract

In previous studies we have elicited T cell-mediated protective immunity to the extra-cellular Gram-negative bacterium Pseudomonas aeruginosa by administering P. aeruginosa polysaccharide Ag and the anti-mitotic agent vinblastine sulfate to BALB/c mice. The current studies indicate that T cells which inhibit the growth of P. aeruginosa in vitro and protect granulocytopenic mice from P. aeruginosa infection can be generated by exposure of BALB/c mice to as few as 10(2) live bacteria without simultaneous administration of vinblastine. The in vitro inhibition of bacterial growth and mouse protection are P. aeruginosa immunotype specific. Exposure to 10(6) live bacteria is required to elicit a detectable antibody response. These findings indicate a potential role for T cells in resistance to P. aeruginosa infection in the large majority of individuals who lack anti-P. aeruginosa antibody.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3126239

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Characterization of T cell clones derived from lymph nodes and lungs of Pseudomonas aeruginosa-susceptible and resistant mice following immunization with heat-killed bacteria.

Authors:  T K Kondratieva; N V Kobets; S V Khaidukov; V V Yeremeev; I V Lyadova; A S Apt; M F Tam; M M Stevenson
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

2.  Protection against pulmonary infection with Pseudomonas aeruginosa following immunization with P. aeruginosa-pulsed dendritic cells.

Authors:  S Worgall; T Kikuchi; R Singh; K Martushova; L Lande; R G Crystal
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

3.  Antibody- and cell-mediated immune responses of Actinobacillus pleuropneumoniae-infected and bacterin-vaccinated pigs.

Authors:  S E Furesz; B A Mallard; J T Bossé; S Rosendal; B N Wilkie; J I MacInnes
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

4.  Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine.

Authors:  Gregory P Priebe; Mary M Brinig; Kazue Hatano; Martha Grout; Fadie T Coleman; Gerald B Pier; Joanna B Goldberg
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

5.  Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant.

Authors:  Gregory P Priebe; Gloria J Meluleni; Fadie T Coleman; Joanna B Goldberg; Gerald B Pier
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

6.  Improved outcome of chronic Pseudomonas aeruginosa lung infection is associated with induction of a Th1-dominated cytokine response.

Authors:  C Moser; P O Jensen; O Kobayashi; H P Hougen; Z Song; J Rygaard; A Kharazmi; N H by
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

7.  Rapid and sensitive method for evaluating Pseudomonas aeruginosa virulence factors during corneal infections in mice.

Authors:  M J Preston; S M Fleiszig; T S Zaidi; J B Goldberg; V D Shortridge; M L Vasil; G B Pier
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

8.  Serum antibody and ocular responses to murine corneal infection caused by Pseudomonas aeruginosa.

Authors:  R S Berk; I N Montgomery; L D Hazlett
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

9.  A role for CD4+ T cells from orally immunized rats in enhanced clearance of Pseudomonas aeruginosa from the lung.

Authors:  M L Dunkley; R L Clancy; A W Cripps
Journal:  Immunology       Date:  1994-11       Impact factor: 7.397

10.  Pseudomonas aeruginosa exoenzyme S induces proliferation of human T lymphocytes.

Authors:  C H Mody; D E Buser; R M Syme; D E Woods
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.